That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. | Tempest Therapeutics is ...

Chico, Vice President and Global Head of Oncology Therapeutic Expertise at Fortrea, shares how scientific advances, AI tools and flexible CRO models are accelerating oncology trials and improving ...

Charles River initially unveiled a plan to adopt new alternative methods (NAMs), like computer models and human organoids, in ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank.

The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. Having put up ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...

Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” according to a new report from PitchBook. | Biotechs will need to be strategic to ...

Shanghai-based VelaVigo has been busy. The biotech granted Avenzo Therapeutics ex-China rights to a Nectin4xTROP2 bispecific ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Should the approach translate to humans, people with allergies may one day be able to take a vaccine that protects them from dangerous allergic reactions.